Molecular and cellular biology of basal cell carcinoma

Australasian Journal of Dermatology

Volumn 43, Issue 4, 2002, Pages 241-246

  Dicker, Tony ^b   Siller, Gregory ^a   Saunders, Nicholas ^a  

^a PRINCESS ALEXANDRA HOSPITAL   (Australia)

^b NONE

Author keywords

Apoptosis; Bcl 2; p53; Patched; TGF

Indexed keywords

FAS ANTIGEN; PROTEIN BCL 2; PROTEIN P53; TELOMERASE; TRANSFORMING GROWTH FACTOR BETA;

APOPTOSIS; BASAL CELL CARCINOMA; CANCER RESEARCH; CYTOLOGY; GENETIC ANALYSIS; HUMAN; MOLECULAR BIOLOGY; REVIEW;

ANTIGENS, CD95; APOPTOSIS; CARCINOMA, BASAL CELL; HUMANS; MEMBRANE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTORS, CELL SURFACE; SKIN NEOPLASMS; TRANSFORMING GROWTH FACTOR BETA; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0036436817     PISSN: 00048380     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-0960.2002.00609.x     Document Type: Review

References (60)

1. Marks R. Epidemiology of non-melanoma skin cancer and solar keratoses in Australia: A tale of self-immolation in Elysian fields. Australas. J. Dermatol. 1997; 38 (Suppl. 1): S26-9.
2. Staples M, Marks R, Giles G. Trends in the incidence of non-melanocytic skin cancer (NMSC) treated in Australia 1985-1995: Are primary prevention programs starting to have an effect? Int. J. Cancer 1998; 78: 144-8.
3. Berti JJ, Sharata HH. Metastatic basal cell carcinoma to the lung. Cutis 1999; 63: 165-6.
4. von Domarus H, Stevens PJ. Metastatic basal cell carcinoma. Report of five cases and review of 170 cases in the literature. J. Am. Acad. Dermatol. 1984; 10: 1043-60.
5. Strutton GM. Pathological variants of basal cell carcinoma. Australas. J. Dermatol. 1997; 38 (Suppl. 1): S31-5.
6. Hahn H, Wicking C, Zaphiropoulous PG, Gailani MR, Shanley S, Chidambaram A et al. Mutations of the human homolog of Drosophila patched in the nevoid basal cell carcinoma syndrome. Cell 1996; 85: 841-51.
7. Johnson RL, Rothman AL, Xie J, Goodrich LV, Bare JW, Bonifas JM et al. Human homolog of patched, a candidate gene for the basal cell nevus syndrome. Science 1996; 272: 1668-71.
8. Gorlin RJ. Nevoid basal cell carcinoma syndrome. Dermatol. Clin. 1995; 13: 113-25.
9. Gailani MR, Stahle-Backdahl M, Leffell DJ, Glynn M, Zaphiropoulos PG, Pressman C et al. The role of the human homologue of Drosophila patched in sporadic basal cell carcinomas. Nat. Genet. 1996; 14: 78-81.
10. Unden AB, Holmberg E, Lundh-Rozell B, Stahle-Backdahl M, Zaphiropoulos PG, Toftgard R, Vorechovsky I. Mutations in the human homologue of Drosophila patched (PTCH) in basal cell carcinomas and the Gorlin syndrome: Different in vivo mechanisms of PTCH inactivation. Cancer Res. 1996; 56: 4562-5.
11. Stone DM, Hynes M, Armanini M, Swanson TA, Gu Q, Johnson RL et al. The tumour-suppressor gene patched encodes a candidate receptor for Sonic hedgehog. Nature 1996; 384: 129-34.
12. Heberlein U, Wolff T, Rubin GM. The TGF beta homolog dpp and the segment polarity gene hedgehog are required for propagation of a morphogenetic wave in the Drosophila retina. Cell 1993; 75: 913-26.
13. Xie J, Aszterbaum M, Zhang X, Bonifas JM, Zachary C, Epstein E, McCormick F. A role of PDGFR alpha in basal cell carcinoma proliferation. Proc. Natl Acad. Sci. USA 2001; 98: 9255-9.
14. Unden AB, Zaphiropoulos PG, Bruce K, Toftgard R, Stahle-Backdahl M. Human patched (PTCH) mRNA is overexpressed consistently in tumor cells of both familial and sporadic basal cell carcinoma. Cancer Res. 1997; 57: 2336-40.
15. Dahmane N, Lee J, Robins P, Heller P, Ruiz i Altaba A. Activation of the transcription factor Gli1 and the Sonic hedgehog signalling pathway in skin tumours. Nature 1997; 389: 876-81.
16. Matise MP, Joyner AL. Gli genes in development and cancer. Oncogene 1999; 18: 7852-9.
17. Barnes EA, Kong M, Ollendorff V, Donoghue DJ. Patched1 interacts with cyclin B1 to regulate cell cycle progression. EMBO J. 2001; 20: 2214-23.
18. Oro AE, Higgins KM, Hu Z, Bonifas JM, Epstein EH Jr, Scott MP. Basal cell carcinomas in mice overexpressing sonic hedgehog. Science 1997; 276: 817-21.
19. Nilsson M, Unden AB, Krause D, Malmqwist U, Raza K, Zaphiropoulos PG, Toftgard R. Induction of basal cell carcinomas and trichoepitheliomas in mice overexpressing GLI-1. Proc. Natl Acad. Sci. USA 2000; 97: 3438-43.
20. Vorechovsky I, Unden AB, Sandstedt B, Toftgard R, Stahle-Backdahl M. Trichoepitheliomas contain somatic mutations in the overexpressed PTCH gene: Support for a gatekeeper mechanism in skin tumorigenesis. Cancer Res. 1997; 57: 4677-81.
21. Sanchez-Herrero E, Couso JP, Capdevila J, Guerrero I. The fu gene discriminates between pathways to control dpp expression in Drosophila imaginal discs. Mech. Dev. 1996; 55: 159-70.
22. Furue M, Kato M, Nakamura K, Nashiro K, Kikuchi K, Okochi H, Miyazono K, Tamaki K. Dysregulated expression of transforming growth factor beta and its type-I and type-II receptors in basal-cell carcinoma. Int. J. Cancer 1997; 71: 505-9.
23. Rollins BJ, O'Connell TM, Bennett G, Burton LE, Stiles CD, Rheinwald JG. Environment-dependent growth inhibition of human epidermal keratinocytes by recombinant human transforming growth factor-beta. J. Cell Physiol. 1989; 139: 455-62.
24. Pasche B. Role of transforming growth factor beta in cancer. J. Cell Physiol. 2001; 186: 153-68.
25. Schmid P, Itin P, Rufli T. In situ analysis of transforming growth factors-beta (TGF-beta 1, TGF-beta 2, TGF-beta 3) and TGF-beta type II receptor expression in basal cell carcinomas. Br. J. Dermatol. 1996; 134: 1044-51.
26. Verhaegh ME, Arends JW, Majoie IM, Hoekzema R, Neumann HA. Transforming growth factor-beta and bcl-2 distribution patterns distinguish trichoepithelioma from basal cell carcinoma. Dermatol. Surg. 1997; 23: 695-700.
27. Stamp GW, Nasim M, Cardillo M, Sudhindra SG, Lalani EN, Pignatelli M. Transforming growth factor-beta distribution in basal cell carcinomas: Relationship to proliferation index. Br. J. Dermatol. 1993; 129: 57-64.
28. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997; 88: 323-31.
29. Barbareschi M, Girlando S, Cristofolini P, Cristofolini M, Togni R, Boi S. p53 protein expression in basal cell carcinomas. Histopathology 1992; 21: 579-81.
30. Shea CR, McNutt NS, Volkenandt M, Lugo J, Prioleau PG, Albino AP. Overexpression of p53 protein in basal cell carcinomas of human skin. Am. J. Pathol. 1992; 141: 25-9.
31. Ponten F, Berg C, Ahmadian A, Ren ZP, Nister M, Lundeberg J, Uhlen M, Ponten J. Molecular pathology in basal cell cancer with p53 as a genetic marker. Oncogene 1997; 15: 1059-67.
32. Demirkan NC, Colakoglu N, Duzcan E. Value of p53 protein in biological behavior of basal cell carcinoma and in normal epithelia adjacent to carcinomas. Pathol. Oncol. Res. 2000; 6: 272-4.
33. Mills AA, Zheng B, Wang XJ, Vogel H, Roop DR, Bradley A. p63 is a p53 homologue required for limb and epidermal morphogenesis. Nature 1999; 398: 708-13.
34. Green DR. Apoptotic pathways: The roads to ruin. Cell 1998; 94: 695-8.
35. Dragovich T, Rudin CM, Thompson CB. Signal transduction pathways that regulate cell survival and cell death. Oncogene 1998; 17: 3207-13.
36. Mooney EE, Ruis Peris JM, O'Neill A, Sweeney EC. Apoptotic and mitotic indices in malignant melanoma and basal cell carcinoma. J. Clin. Pathol. 1995; 48: 242-4.
37. Olson RL, Everett MA. Epidermal apoptosis: Cell deletion by phagocytosis. J. Cutan. Pathol. 1975; 2: 53-7.
38. Rodriguez-Villanueva J, Colome MI, Brisbay S, McDonnell TJ. The expression and localization of bcl-2 protein in normal skin and in non-melanoma skin cancers. Pathol. Res. Pract. 1995; 191: 391-8.
39. Verhaegh ME, Sanders CJ, Arends JW, Neumann HA. Expression of the apoptosis-suppressing protein Bcl-2 in non-melanoma skin cancer. Br. J. Dermatol. 1995; 132: 740-4.
40. Cerroni L, Kerl H. Aberrant bcl-2 protein expression provides a possible mechanism of neoplastic cell growth in cutaneous basal-cell carcinoma. J. Cutan. Pathol. 1994; 21: 398-403.
41. Morales-Ducret CR, Van de Rijn M, LeBrun DP, Smoller BR. bcl-2 expression in primary malignancies of the skin. Arch. Dermatol. 1995; 131: 909-12.
42. Abdelsayed RA, Guijarro-Rojas M, Ibrahim NA, Sangueza OP. Immunohistochemical evaluation of basal cell carcinoma and trichoepithelioma using Bcl-2, Ki67, PCNA and P53. J. Cutan. Pathol. 2000; 27: 169-75.
43. Poniecka AW, Alexis JB. An immunohistochemical study of basal cell carcinoma and trichoepithelioma. Am. J. Dermatopathol. 1999; 21: 332-6.
44. Swanson PE, Fitzpatrick MM, Ritter JH, Glusac EJ, Wick MR. Immunohistologic differential diagnosis of basal cell carcinoma, squamous cell carcinoma, and trichoepithelioma in small cutaneous biopsy specimens. J. Cutan. Pathol. 1998; 25: 153-9.
45. Smoller BR, Van de Rijn M, Lebrun D, Warnke RA. bcl-2 expression reliably distinguishes trichoepitheliomas from basal cell carcinomas. Br. J. Dermatol. 1994; 131: 28-31.
46. Ramdial PK, Madaree A, Reddy R, Chetty R. bcl-2 protein expression in aggressive and non-aggressive basal cell carcinomas. J. Cutan. Pathol. 2000; 27: 283-91.
47. Crowson AN, Magro CM, Kadin ME, Stranc M. Differential expression of the bcl-2 oncogene in human basal cell carcinoma. Hum. Pathol. 1996; 27: 355-9.
48. Rossen K, Karabulut Thorup A, Hou-Jensen K, Krag Jacobsen G. BAX protein is not expressed by basal cell carcinomas. Br. J. Dermatol. 1998; 139: 472-4.
49. Tomkova H, Fujimoto W, Arata J. Expression of the bcl-2 homologue bax in normal human skin, psoriasis vulgaris and non-melanoma skin cancers. Eur. J. Dermatol. 1998; 8: 256-60.
50. Wikonkal NM, Berg RJ, van Haselen CW, Horkay I, Remenyik E, Begany A, Hunyadi J, van Vloten WA, de Gruijl FR. bcl-2 vs p53 protein expression and apoptotic rate in human nonmelanoma skin cancers. Arch. Dermatol. 1997; 133: 599-602.
51. Lee SH, Jang JJ, Lee JY, Kim SY, Park WS, Shin MSet al. Fas ligand is expressed in normal skin and in some cutaneous malignancies. Br. J. Dermatol. 1998; 139: 186-91.
52. Gutierrez-Steil C, Wrone-Smith T, Sun X, Krueger JG, Coven T, Nickoloff BJ. Sunlight-induced basal cell carcinoma tumor cells and ultraviolet-B-irradiated psoriatic plaques express Fas ligand (CD95L). J. Clin. Invest. 1998; 101: 33-9.
53. Buechner SA, Wernli M, Harr T, Hahn S, Itin P, Erb P. Regression of basal cell carcinoma by intralesional interferon-alpha treatment is mediated by CD95 (Apo-1/Fas)-CD95 ligand-induced suicide. J. Clin. Invest. 1997; 100: 2691-6.
54. Harley CB, Futcher AB, Greider CW. Telomeres shorten during ageing of human fibroblasts. Nature 1990; 345: 458-60.
55. Chen Z, Smith KJ, Skelton HG III, Barrett TL, Greenway HT Jr, Lo SC. Telomerase activity in Kaposi's sarcoma, squamous cell carcinoma, and basal cell carcinoma. Exp. Biol. Med. (Maywood) 2001; 226: 753-7.
56. Parris CN, Jezzard S, Silver A, MacKie R, McGregor JM, Newbold RF. Telomerase activity in melanoma and nonmelanoma skin cancer. Br. J. Cancer 1999; 79: 47-53.
57. Ogoshi M, Le T, Shay JW, Taylor RS. In situ hybridization analysis of the expression of human telomerase RNA in normal and pathologic conditions of the skin. J. Invest. Dermatol. 1998; 110: 818-23.
58. Smith KJ, Williams J, Corbett D, Skelton H. Microcystic adnexal carcinoma: An immunohistochemical study including markers of proliferation and apoptosis. Am. J. Surg. Pathol. 2001; 25: 464-71.
59. Boonchai W, Walsh M, Cummings M, Chenevix-Trench G. Expression of p53 in arsenic-related and sporadic basal cell carcinoma. Arch. Dermatol. 2000; 136: 195-8.
60. Taipale J, Chen JK, Cooper MK, Wang B, Mann RK, Milenkovic L, Scott MP, Beachy PA. Effects of oncogenic mutations in smoothened and patched can be reversed by cyclopamine. Nature 2000; 406: 1005-9.